Editorial: and genome engineering for metabolic and neurometabolic diseases.
作者信息
Colella Pasqualina, Meneghini Vasco, Baldo Guilherme, Gomez-Ospina Natalia
机构信息
Department of Pediatrics, Stanford University, Stanford, CA, United States.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
出版信息
Front Genome Ed. 2023 Jul 6;5:1248904. doi: 10.3389/fgeed.2023.1248904. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: and genome engineering for metabolic and neurometabolic diseases.社论：代谢和神经代谢疾病的基因编辑技术
Front Genome Ed. 2023 Jul 6;5:1248904. doi: 10.3389/fgeed.2023.1248904. eCollection 2023.
2
Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing.对同源定向修复（HDR）和非同源末端连接（NHEJ）的系统定量揭示了基因座、核酸酶和细胞类型对基因组编辑的影响。
Sci Rep. 2016 Mar 31;6:23549. doi: 10.1038/srep23549.
3
Detection and Quantification of HDR and NHEJ Induced by Genome Editing at Endogenous Gene Loci Using Droplet Digital PCR.使用液滴数字PCR检测和定量内源基因位点基因组编辑诱导的同源重组修复和非同源末端连接
Methods Mol Biol. 2018;1768:349-362. doi: 10.1007/978-1-4939-7778-9_20.
4
Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems.靶向同源定向修复实现精确基因编辑的前沿趋势：小分子与改良CRISPR-Cas9系统的综合综述
Bioimpacts. 2022;12(4):371-391. doi: 10.34172/bi.2022.23871. Epub 2022 Jun 22.
5
Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes.用于小鼠胚胎干细胞和受精卵的高效CRISPR/HDR介导的基因敲入
Biotechniques. 2015 Oct 1;59(4):201-2, 204, 206-8. doi: 10.2144/000114339. eCollection 2015 Oct.
6
CRISPR-Cpf1-Assisted Multiplex Genome Editing and Transcriptional Repression in Streptomyces.CRISPR-Cpf1 辅助的链霉菌多重基因组编辑和转录抑制
Appl Environ Microbiol. 2018 Aug 31;84(18). doi: 10.1128/AEM.00827-18. Print 2018 Sep 15.
7
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies.体内基因组编辑作为遗传性视网膜营养不良的一种潜在治疗策略。
Prog Retin Eye Res. 2017 Jan;56:1-18. doi: 10.1016/j.preteyeres.2016.09.001. Epub 2016 Sep 10.
8
Modulating DNA Repair Pathways to Improve Precision Genome Engineering.调控 DNA 修复途径以提高精确基因组工程。
ACS Chem Biol. 2018 Feb 16;13(2):389-396. doi: 10.1021/acschembio.7b00777. Epub 2017 Dec 20.
9
Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.理解和克服基因组编辑对造血干细胞和祖细胞的不良后果。
Mol Ther. 2021 Nov 3;29(11):3205-3218. doi: 10.1016/j.ymthe.2021.09.001. Epub 2021 Sep 10.
10
CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites.CRISPR-Cas9 融合到显性失活 53BP1 中可特异性增强 HDR 并抑制 NHEJ 在 Cas9 靶位点处。
Nat Commun. 2019 Jun 28;10(1):2866. doi: 10.1038/s41467-019-10735-7.
引用本文的文献
1
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
2
Advancements in genome editing tools for genetic studies and crop improvement.用于基因研究和作物改良的基因组编辑工具的进展。
Front Plant Sci. 2025 Feb 3;15:1370675. doi: 10.3389/fpls.2024.1370675. eCollection 2024.
本文引用的文献
1
First hemophilia B gene therapy approved: More than two decades in the making.首个血友病B基因疗法获批：历经二十余载研发而成。
Mol Ther. 2023 Jan 4;31(1):1-2. doi: 10.1016/j.ymthe.2022.12.001. Epub 2022 Dec 16.
2
Adeno-Associated Virus Gene Therapy for Hemophilia.腺相关病毒基因治疗血友病。
Annu Rev Med. 2023 Jan 27;74:231-247. doi: 10.1146/annurev-med-043021-033013. Epub 2022 Sep 14.
3
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.慢病毒造血干细胞基因治疗早发性异染性脑白质营养不良：1/2 期非随机、开放标签、单臂临床试验及扩大使用的长期结果。
Lancet. 2022 Jan 22;399(10322):372-383. doi: 10.1016/S0140-6736(21)02017-1.
4
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome.用于黏多糖贮积症I型的造血干细胞和祖细胞基因疗法
N Engl J Med. 2021 Nov 18;385(21):1929-1940. doi: 10.1056/NEJMoa2106596.
5
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.CRISPR-Cas9 体内基因编辑治疗转甲状腺素蛋白淀粉样变性。
N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
6
CRISPR gene therapy shows promise against blood diseases.CRISPR基因疗法对治疗血液疾病显示出前景。
Nature. 2020 Dec;588(7838):383. doi: 10.1038/d41586-020-03476-x.
7
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
8
Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases.遗传性单基因疾病临床体外造血干细胞基因治疗进展。
Mol Ther. 2021 Feb 3;29(2):489-504. doi: 10.1016/j.ymthe.2020.11.020. Epub 2020 Nov 20.
9
High levels of AAV vector integration into CRISPR-induced DNA breaks.高水平的 AAV 载体整合到 CRISPR 诱导的 DNA 断裂中。
Nat Commun. 2019 Sep 30;10(1):4439. doi: 10.1038/s41467-019-12449-2.
10
Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.人类基因组编辑造血干细胞在表型上纠正黏多糖贮积症 I 型。
Nat Commun. 2019 Sep 6;10(1):4045. doi: 10.1038/s41467-019-11962-8.
Zotero 插件